Cerenome’s CNSide Diagnostics has selected XiFin to provide automated revenue cycle management for its cerebrospinal fluid assay platform, aiming to support increased test volumes and streamline billing as payer coverage expands.
The FDA will review GRAIL’s Premarket Approval application for the Galleri multi-cancer early detection blood test on Sept 23, 2026, evaluating data from the PATHFINDER 2 and NHS-Galleri studies.
ADLM 2026 drew nearly 17,000 professionals to Anaheim, where experts discussed advances in space diagnostics, mass spectrometry, and chronic disease management, and Kompass Diagnostics won the Disruptive Technology Award for its IDA platform.
ProtaGene’s Heidelberg, Germany, lab has received CAP and CLIA accreditation, authorizing integration site analysis on human samples for lentivirus-based cell and gene therapy under U.S. federal regulations.
The Problem Solvers Caucus has endorsed the bipartisan RESULTS Act (HR 5269), which aims to modernize the Medicare Clinical Laboratory Fee Schedule and prevent scheduled payment cuts to lab services beginning in 2027.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
SOPHiA GENETICS and AstraZeneca have signed a multi-year agreement to develop and deploy decentralized companion diagnostics for solid tumors and blood cancers, aiming to expand local lab access to precision oncology testing.
Position your laboratory for the future of hemostasis testing This sponsored white paper explores how advances in automation, workflow optimization, and intelligent coagulation analysis are helping laboratories improve...